Pharmacogenetics of obsessive-compulsive disorders

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 71-81

  Brandl, Eva J ^a   Müller, Daniel J ^a   Richter, Margaret A ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

BDNF; Brain derived neurotrophic factor; Cytochrome system; Genetics; Glutamate transporter; Obsessive compulsive disorder; Pharmacogenetics; Serotonin; Treatment response

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CLOMIPRAMINE; CYTOCHROME; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; FLUOXETINE; FLUVOXAMINE; GLUTAMATE TRANSPORTER; GUANINE; METHIONINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALINE; VENLAFAXINE;

AMINO ACID SUBSTITUTION; BRAIN DERIVED NEUROTROPHIC FACTOR GENE; COGNITIVE THERAPY; COMT GENE; CYP2C19 GENE; CYP2D19 GENE; CYP2D6 GENE; DEMOGRAPHY; DISEASE SEVERITY; DRD2 GENE; DRD4 GENE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLUTAMATE TRANSPORTER GENE; HEREDITY; HUMAN; INHIBITION KINETICS; MAOA GENE; OBSESSIVE COMPULSIVE DISORDER; PHARMACOGENETICS; REVIEW; SEROTONIN GENE; SEROTONIN UPTAKE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; BIOTRANSFORMATION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOCHROMES; EXCITATORY AMINO ACID TRANSPORTER 3; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; POLYMORPHISM, GENETIC; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 83755195423     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.133     Document Type: Review

References (101)

1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry 15(1), 53-63 (2010).
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - DSM-IV-TR (4th Edition, Text Revision). American Psychiatric Association, Washington, DC, USA (2000).
3. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Critera for Research. World Health Organization, Geneva, Switzerland (1992).
4. Walitza S, Renner TJ, Wewetzer C, Warnke A. Genetic findings in obsessive-compulsive disorder in childhood and adolescence and in adulthood. Z. Kinder Jugendpsychiatr. Psychother. 36(1), 45-52 (2008). (Pubitemid 351223985)
5. Nicolini H, Arnold P, Nestadt G, Lanzagorta N, Kennedy JL. Overview of genetics and obsessive-compulsive disorder. Psychiatry Res. 170(1), 7-14 (2009).
6. Jonnal AH, Gardner CO, Prescott CA, Kendler KS. Obsessive and compulsive symptoms in a general population sample of female twins. Am. J. Med. Genet. 96(6), 791-796 (2000). (Pubitemid 32093913)
7. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: A review. Twin Res. Hum. Genet. 8(5), 450-458 (2005). (Pubitemid 41499486)
8. Mathews CA, Greenwood T, Wessel J et al. Evidence for a heritable unidimensional symptom factor underlying obsessionality. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(6), 676-685 (2008).
9. Katerberg H, Delucchi KL, Stewart SE et al. Symptom dimensions in OCD: item-level factor analysis and heritability estimates. Behav. Genet. 40(4), 505-517 (2010).
10. Nestadt G, Samuels J, Riddle M et al. A family study of obsessive-compulsive disorder. Arch. Gen. Psychiatry 57(4), 358-363 (2000). (Pubitemid 30202326)
11. Grados MA, Walkup J, Walford S. Genetics of obsessive-compulsive disorders: new findings and challenges. Brain Dev. (Suppl. 1), S55-S61 (2003). (Pubitemid 39658652)
12. Pauls DL. The genetics of obsessive-compulsive disorder: A review. Dialogues Clin. Neurosci. 12(2), 149-163 (2010).
13. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 30(3), 327-337 (2006).
14. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. American Psychiatric Press, Inc., Arlington, VA, USA (2007).
15. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry 60(2), 101-106 (1999). (Pubitemid 29104386)
16. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N. Engl. J. Med. 350(3), 259-265 (2004).
17. Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol. Psychiatry 15(8), 850-855 (2010).
18. Goodwin G, Fleischhacker W, Arango C et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur. Neuropsychopharmacol. 19(7), 520-532 (2009).
19. Denys D, Burger H, van Megen H, de Geus F, Westenberg H. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 18(6), 315-322 (2003). (Pubitemid 38183484)
20. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J. Clin. Psychiatry 56(8), 368-373 (1995).
21. Shetti CN, Reddy YC, Kandavel T et al. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J. Clin. Psychiatry 66(12), 1517-1523 (2005). (Pubitemid 43068689)
22. Ackerman DL, Greenland S, Bystritsky A, Morgenstern H, Katz RJ. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J. Clin. Psychopharmacol. 14(4), 247-254 (1994). (Pubitemid 24254716)
23. Langner J, Laws M, Röper G, Zaudig M, Hauke W, Piesbergen C. Predicting therapy outcome in patients with early and late obsessive-compulsive disorder (EOCD and LOCD). Behav. Cogn Psychother. 37(5), 485-496 (2009).
24. Salomoni G, Grassi M, Mosini P, Riva P, Cavedini P, Bellodi L. Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response. J. Clin. Psychopharmacol. 29(4), 343-349 (2009).
25. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev. 32(3), 525-549 (2008). (Pubitemid 351173336)
26. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res. 132(1), 69-79 (2004). (Pubitemid 39531326)
27. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin. North Am. 23(3), 563-586 (2000). (Pubitemid 30666507)
28. Friedlander L, Desrocher M. Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clin. Psychol. Rev. 26(1), 32-49 (2006). (Pubitemid 41803610)
29. Nakao T, Nakagawa A, Yoshiura T, Nakatani E et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: A functional magnetic resonance imaging study. Bio. Psychiatry 57(8), 901-910 (2005). (Pubitemid 40488359)
30. Lázaro L, Caldú X, Junqué C et al. Cerebral activation in children and adolescents with obsessive-compulsive disorder before and after treatment: A functional MRI studz. J. Psychiatr. Res. 42(13), 1051-1059 (2008).
31. Sanematsu H, Nakao T, Yoshiura T et al. Predictors of treatment response to fluvoxamine in obsessive-compulsive disorder: an fMRI study. J. Psychiatr. Res. 44(4), 193-200 (2010).
32. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004). (Pubitemid 38903502)
33. Deupree JD, Montgomery MD, Bylund DB. Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram. Eur. J. Pharmacol. 576(1-3), 55-60 (2007). (Pubitemid 47588258)
34. Katoh Y, Uchida S, Kawai M et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol. Pharm. Bull. 33(2), 285-288 (2010).
35. Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur. J. Clin. Pharmacol. 64(4), 381-385 (2008). (Pubitemid 351322359)
36. Kirchheiner J, Seeringer A, Godoy AL et al. CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatry 16(3), 237, 333-341 (2011).
37. Kirchheiner J, Brøsen K, Dahl ML et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104(3), 173-192 (2001). (Pubitemid 32762271)
38. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47(1), 75-85 (2006). (Pubitemid 43017126)
39. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin. Neurosci. 12(1), 69-76 (2010).
40. Baumann P, Barbe R, Vabre-Bogdalova A, Garran E, Crettol S, Eap CB. Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. J. Clin. Psychopharmacol. 26(6), 679-681 (2006). (Pubitemid 44772757)
41. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int. J. Psychiatry Clin. Pract. 13(1), 345-348 (2009).
42. Müller DJ, Sturgess JE, Likhodi O et al. The pharmacogenetics research clinic: first steps towards the implementation of CYP2D6 and CYP2C19 genotyping in psychiatric practice. Presented at: The 18th World Congress on Psychiatric Genetics. Athens, Greece, 3-7 October 2010.
43. Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl Acad. Sci. USA 90(6), 2542-2546 (1993). (Pubitemid 23078664)
44. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66(6), 2621-2624 (1996). (Pubitemid 26159101)
45. Hu XZ, Lipsky RH, Zhu G et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78(5), 815-826 (2006).
46. Rocha FF, Marco LA, Romano-Silva MA, Corra H. Obsessive-compulsive disorder and 5 HTTLPR. Rev. Bras. Psiquiatr. 31(3), 287-288 (2009).
47. Billett EA, Richter MA, King N, Heils A, Lesch KP, Kennedy JL. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol. Psychiatry 2(5), 403-406 (1997). (Pubitemid 127702161)
48. Bloch MH, Landeros-Weisenberger A, Sen S et al. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(6), 850-858 (2008).
49. Zitterl W, Stompe T, Aigner M et al. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Biol. Psychiatry 66(12), 1115-1122 (2009).
50. Serretti A, Kato M, De Ronchi D et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5 HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12(3), 247-257 (2007). (Pubitemid 46328503)
51. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol. Psychiatry 3(3), 270-273 (1998). (Pubitemid 28266338)
52. Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-compulsive disorder, 5 HTTLPR polymorphism and treatment response. Pharmacogenomics J. 2(3), 176-181 (2002). (Pubitemid 34982225)
53. Zhang L, Liu X, Li T, Yang Y, Hu X, Collier D. Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(5), 479-481 (2004). (Pubitemid 39371437)
54. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J. Clin. Psychiatry 68(5), 747-753 (2007). (Pubitemid 46841858)
55. Miguita K, Cordeiro Q, Shavitt RG, Miguel EC, Vallada H. Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment. Arq. Neuropsiquiatr. 69(2B), 283-287 (2011).
56. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur. Neuropsychopharmacol. 8(4), 325-328 (1998). (Pubitemid 28557029)
57. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5 HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am. J. Psychiatry 157(7), 1160-1161 (2000). (Pubitemid 30432500)
58. Mundo E, Richter MA, Zai G et al. 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol. Psychiatry 7(7), 805-809 (2002). (Pubitemid 34984961)
59. Di Bella D, Cavallini MC, Bellodi L. No association between obsessive-compulsive disorder and the 5 HT(1Dbeta) receptor gene. Am. J. Psychiatry. 159(10), 1783-1785 (2002).
60. Camarena B, Aguilar A, Loyzaga C, Nicolini H. A family-based association study of the 5 HT-1Dbeta receptor gene in obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 7(1), 49-53 (2004). (Pubitemid 38523806)
61. Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J. Clin. Psychiatry 65(Suppl. 14), 18-21 (2004).
62. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 1074-1084 (2005). (Pubitemid 41080134)
63. Meyer JH, Kapur S, Eisfeld B et al. The effect of paroxetine on 5 HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry. 158(1), 78-85 (2001). (Pubitemid 32047250)
64. Horstmann S, Lucae S, Menke A et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3), 727-740 (2010).
65. Lucae S, Ising M, Horstmann S et al. HTR2A gene variation is involved in antidepressant treatment response. Eur. Neuropsychopharmacol. 20(1), 65-68 (2010).
66. McMahon FJ, Buervenich S, Charney D et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 78(5), 804-814 (2006).
67. Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 9(4), 225-233 (2009).
68. Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of serotonin receptor 2A (HTR2A), interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med. 13(1), 66-76 (2011).
69. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D. 5 HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. Lancet 351(9118), 1785-1786 (1998). (Pubitemid 28269194)
70. Liu W, Zhao N, Xiong J, Shi M, Hu J. Associated analysis of serotonin and catecholamine system candidate genes in obsessive-compulsive disorder in the Chinese population. Psychiatry Res. 188(1), 170-172 (2011).
71. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O. T102C and -1438 G/A polymorphisms of the 5 HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur. Psychiatry 18(5), 249-254 (2003). (Pubitemid 37010317)
72. Zai G, Likhodi O, Arnold PD, Sicard T, Burroughs EB, Richter MA. A role for the serotonin receptor gene 5HTR2A in predicting SRI response in obsessive-compulsive disorder. Presented at: The 8th Pharmacogenetics in Psychiatry Meeting. New York, NY, USA 17-18 April 2009.
73. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol. Disord. Drug Targets 7(1), 46-62 (2008). (Pubitemid 351516216)
74. Mössner R, Daniel S, Albert D et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem. Int. 36(3), 197-202 (2000). (Pubitemid 30047011)
75. Deltheil T, Guiard BP, Guilloux JP et al. Consequences of changes in BDNF levels on serotonin neurotransmission, 5 HT transporter expression and function: studies in adult mice hippocampus. Pharmacol. Biochem. Behav. 90(2), 174-183 (2008). (Pubitemid 351795580)
76. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry 15(5), 473-500 (2010).
77. Chen ZY, Patel PD, Sant G et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J. Neurosci. 24(18), 4401-4411 (2004). (Pubitemid 38608151)
78. Bath KG, Lee FS. Variant BDNF (Val- 66Met) impact on brain structure and function. Cogn. Affect. Behav. Neurosci. 6(1), 79-85 (2006).
79. Hemmings SM, Kinnear CJ, Van der Merwe L et al. Investigating the role of the brain-derived neurotrophic factor (BDNF) val-66met variant in obsessive-compulsive disorder (OCD). World J. Biol. Psychiatry 9(2), 126-134 (2008). (Pubitemid 351567037)
80. Katerberg H, Lochner C, Cath DC et al. The role of the brain-derived neurotrophic factor (BDNF) val-66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B(8), 1050-1062 (2009).
81. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am. J. Hum. Genet. 73(2), 370-376 (2003). (Pubitemid 36920998)
82. Dickel DE, Veenstra-VanderWeele J, Bivens NC et al. Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder. Biol. Psychiatry 61(3), 322-329 (2007). (Pubitemid 46108693)
83. Zai G, Arnold P, Strauss J et al. No association between brain-derived neurotrophic factor gene and obsessive-compulsive disorder. Psychiatr. Genet. 15(4), 235 (2005). (Pubitemid 44491458)
84. Real E, Gratacòs M, Soria V, Escaramís G et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol. Psychiatry 66(7), 674-680 (2009).
85. Zai G, Richter MA, Zai C, Burroughs E, Kennedy JL. Meta-analysis of brain-derived neurotrophic factor (BDNF) Val-66Met polymorphism association and antidepressant response in patients with OCD. Presented at: The 18th World Congress on Psychiatric Genetics. Athens, Greece, 3-7 October 2010.
86. Rosenberg DR, Hanna GL. Genetic and imaging strategies in obsessive-compulsive disorder: potential implications for treatment development. Biol. Psychiatry 48(12), 1210-1222 (2000). (Pubitemid 32008444)
87. Hanna GL, Veenstra-VanderWeele J, Cox NJ et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am. J. Med. Genet. 114(5), 541-552 (2002). (Pubitemid 34680583)
88. Willour VL, Yao Shugart Y, Samuels J et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am. J. Hum. Genet. 75(3), 508-513 (2004). (Pubitemid 39095826)
89. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32(1), 1-14 (2000).
90. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiatry 63(7), 769-776 (2006).
91. Dickel DE, Veenstra-Vander Weele J, Cox NJ et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch. Gen. Psychiatry 63(7), 778-785 (2006).
92. Wendland JR, Moya PR, Timpano KR et al. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch. Gen. Psychiatry 66(4), 408-416 (2009).
93. Wang Y, Adamczyk A, Shugart YY et al. A screen of SLC1A1 for OCD-related alleles. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(2), 675-679 (2010).
94. Kwon JS, Joo YH, Nam HJ et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch. Gen. Psychiatry 66(11), 1233-1241 (2009).
95. Real E, Gratacòs M, Alonso P et al. Pharmacological resistance level in OCD patients without a stressful life event at onset of the disorder is associated with a polymorphism of the gluatamte transporter gene (SLC1A1). Presented at: The 18th World Congress on Psychiatric Genetics. Athens, Greece, 3-7 October 2010.
96. Lin PI, Vance JM, Pericak-Vance MA, Martin ER. No gene is an island: the flip-flop phenomenon. Am. J. Hum. Genet. 80(3), 531-538 (2007).
97. Arnold PD, Richter MA. Genetics of obsessive-compulsive disorder: evidence from pediatric and adult studies. In: A Comprehensive Handbook of Child and Adolescent Obsessive-Compulsive Disorder. Storch EA, Murphy T, Geffken G (Eds). Lawrence Erlbaum Associates, Inc., Mahwah, NJ, USA, 175-212 (2007).
98. Miguel EC, Leckman JF, Rauch S et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol. Psychiatry 10(3), 258-275 (2005). (Pubitemid 40432680)
99. Hoexter MQ, Shavitt RG, D'Alcante CC et al. The drug-naive OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. Rev. Bras. Psiquiatr. 31(4), 349-353 (2009).
100. Daly AK. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11(4), 241-246 (2010).
101. Licinio J, Wong ML. Pharmacogenomics of antidepressant treatment effects. Dialogues Clin. Neurosci. 13(1), 63-71 (2011).